HypertensionPub Date : 2025-01-01Epub Date: 2024-11-14DOI: 10.1161/HYPERTENSIONAHA.124.23549
Giuseppe Mancia, Rita Facchetti, Fosca Quarti-Trevano, Guido Grassi
{"title":"Reproducibility and Treatment Effect on Office and Ambulatory Pressure Relation.","authors":"Giuseppe Mancia, Rita Facchetti, Fosca Quarti-Trevano, Guido Grassi","doi":"10.1161/HYPERTENSIONAHA.124.23549","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23549","url":null,"abstract":"<p><strong>Background: </strong>In the absence of outcome-based ambulatory blood pressure (BP) trails hypertension guidelines provide 24-hour mean BP values corresponding to trial-validated office BP values. Data are shown for untreated and treated patients together, but whether corresponding ambulatory values are similar in untreated and treated hypertensives and reproducible at yearly measurements during treatment is undefined.</p><p><strong>Methods: </strong>In 2397 patients of the ELSA (European Lacidipine Study on Atherosclerosis) and PHYLLIS (Plaque Hypertension Lipid-Lowering Italian Study) trials, we calculated the office and 24-hour BP relationship according to the linear regression model, with office systolic BP as the independent variable, at baseline and yearly during a 3-year treatment. Twenty-four hour BP values corresponding to clinically important office BP values (hypertension grading and treatment thresholds and targets) were calculated and compared with those provided by guidelines.</p><p><strong>Results: </strong>Office and 24-hour systolic BP or diastolic BP always exhibited a significant linear relationship, with, however, limited Pearson correlation coefficients (never >0.44).The slopes of the relationship were superimposable between different years of treatment but always significantly less steep than the slope seen in untreated individuals. Compared with the guideline-provided corresponding values, 24-hour BP showed qualitative and quantitative differences; for example, it was considerably lower and higher than the guideline-corresponding values when office BP was in the high hypertension and low treatment target ranges, respectively.</p><p><strong>Conclusions: </strong>In treated patients with hypertension the slope of the office and 24-hour BP linear regression is reproducible over time. However, the slopes are steeper in untreated individuals, indicating that information on ambulatory BP values corresponding to office BP values can be more accurate if separately estimated in these 2 conditions.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"126-135"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-11-06DOI: 10.1161/HYPERTENSIONAHA.124.23194
Soumiya Pal, Ashim K Bagchi, David S Henry, Reid D Landes, Shengyu Mu, Sung W Rhee, Nancy J Rusch, Amanda J Stolarz
{"title":"Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats.","authors":"Soumiya Pal, Ashim K Bagchi, David S Henry, Reid D Landes, Shengyu Mu, Sung W Rhee, Nancy J Rusch, Amanda J Stolarz","doi":"10.1161/HYPERTENSIONAHA.124.23194","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23194","url":null,"abstract":"<p><strong>Background: </strong>Hypertension increases the risk of lymphedema in patients with comorbidities, but whether hypertension directly compromises lymph vessel (LV) function and lymph flow is unclear. We compared the contractions of mesenteric LVs ex vivo and lymph flow in vivo between normotensive and Ang II (angiotensin II)-induced hypertensive rats and explored the ionic basis of contractile patterns. Key studies were recapitulated in spontaneously hypertensive rats and control Wistar-Kyoto rats.</p><p><strong>Methods: </strong>Video microscopy continuously recorded the diameters of cannulated rat mesenteric LVs, and high-speed optical imaging estimated mesenteric lymph flow in vivo. Jess capillary Western electrophoresis evaluated expression levels of ion channel proteins.</p><p><strong>Results: </strong>Isolated LVs from Ang II-induced hypertensive rats exhibited dysrhythmic contractions, whereas LVs from both Ang II-induced hypertensive rats and spontaneously hypertensive rats exhibited reduced diastolic diameters and cross-sectional flow. Mesenteric lymph flow in vivo was 2.9-fold lower in Ang II-induced hypertensive rats compared with normotensive rats. Surprisingly, the LVs from Ang II-induced hypertensive rats expressed fewer intact L-type Ca<sup>2+</sup> channel pore proteins and more modulatory cleaved C-terminal fragments. However, pharmacological block of voltage-gated K<sup>+</sup> channels but not other K<sup>+</sup> channel types in control LVs established the pattern of contractile dysfunction observed in hypertension. Jess capillary Western electrophoresis analysis confirmed a loss of Shaker-type K<sub>V</sub>1.2 channels in LVs from hypertensive rats.</p><p><strong>Conclusions: </strong>We provide initial evidence of lymphatic contractile dysfunction and compromised lymph flow in hypertensive rats, which may be caused by a loss of K<sub>V</sub>1.2 channels in the lymphatic muscle cells.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"72-83"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-11-13DOI: 10.1161/HYPERTENSIONAHA.124.23695
Katlyn E McGraw, Arce Domingo-Relloso, Daniel W Riggs, Danielle N Medgyesi, Raghavee Neupane, Jeanette A Stingone, Tiffany R Sanchez
{"title":"Exposure to Volatile Organic Compounds and Blood Pressure in NHANES 2011 to 2018.","authors":"Katlyn E McGraw, Arce Domingo-Relloso, Daniel W Riggs, Danielle N Medgyesi, Raghavee Neupane, Jeanette A Stingone, Tiffany R Sanchez","doi":"10.1161/HYPERTENSIONAHA.124.23695","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23695","url":null,"abstract":"<p><strong>Background: </strong>Volatile organic compounds (VOCs) are ubiquitous environmental pollutants. Exposure to VOCs is associated with cardiovascular disease risk factors, including elevated blood pressure in susceptible populations. However, research in the general population, particularly among nonsmoking adults, is limited. We hypothesized that higher VOC exposure is associated with higher blood pressure and hypertension, among nonsmokers.</p><p><strong>Methods: </strong>We included 4 cycles of data (2011-2018) of nonsmoking adults (n=4430) from the National Health and Nutrition Examination Survey. Urinary VOC metabolites were measured by ultraperformance liquid chromatography-mass spectrometry, adjusted for urine dilution, and log-transformed. We estimated mean differences in blood pressure using linear models and prevalence ratio of stage 2 hypertension using modified Poisson models with robust standard errors. Models were adjusted for age, sex, race and ethnicity, education, body mass index, estimated glomerular filtration rate, and National Health and Nutrition Examination Survey cycle.</p><p><strong>Results: </strong>Participants were 54% female, with a median age of 48 years, 32.3% had hypertension, and 7.9% had diabetes. The mean differences (95% CI) in systolic blood pressure were 1.61 (0.07-3.15) and 2.46 (1.01-3.92) mm Hg when comparing the highest with the lowest quartile of urinary acrolein (N-acetyl-S-[2-carboxyethyl]-L-cysteine) and 1,3-butadiene (N-acetyl-S-[3,4-dihydroxybutyl]-L-cysteine) metabolites. The prevalence ratios for hypertension were 1.06 (95% CI, 1.02-1.09) and 1.05 (95% CI, 1.01-1.09) when comparing the highest with lowest quartiles of urinary acrolein (N-acetyl-S-[2-carboxyethyl]-L-cysteine) and 1,3-butadiene (N-acetyl-S-[3,4-dihydroxybutyl]-L-cysteine), respectively.</p><p><strong>Conclusions: </strong>Exposure to VOCs may be a relevant yet understudied environmental contributor to cardiovascular disease risk in the nonsmoking, US population.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"136-148"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-12-18DOI: 10.1161/HYPERTENSIONAHA.124.24124
Alejandro Mata-Daboin, Jonathan H Jaggar
{"title":"Endothelial Cell TRPV4 Channels Turn to the Dark Side During Hypertension.","authors":"Alejandro Mata-Daboin, Jonathan H Jaggar","doi":"10.1161/HYPERTENSIONAHA.124.24124","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24124","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"82 1","pages":"69-71"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-09-16DOI: 10.1161/HYPERTENSIONAHA.124.23722
Aletta E Schutte, Garry L R Jennings
{"title":"To Harmonize or to Hinder … Do We Need 2 Sets of European Hypertension Guidelines in 2024?","authors":"Aletta E Schutte, Garry L R Jennings","doi":"10.1161/HYPERTENSIONAHA.124.23722","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23722","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"8-10"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142285904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-09-16DOI: 10.1161/HYPERTENSIONAHA.124.23724
Jordana B Cohen
{"title":"What Is New in the ESC Hypertension Guideline?","authors":"Jordana B Cohen","doi":"10.1161/HYPERTENSIONAHA.124.23724","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23724","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"11-13"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142285905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-11-27DOI: 10.1161/HYPERTENSIONAHA.124.23196
Mona Elgazzaz, Navya Lakkappa, Clara Berdasco, Uma Priya Mohan, Anna Nuzzo, Luke Restivo, Alexa Martinez, Amy Scarborough, Jessie J Guidry, Srinivas Sriramula, Jiaxi Xu, Hisham Daoud, Michelle A Mendiola Plá, Dawn E Bowles, Andreas M Beyer, Franck Mauvais-Jarvis, Xinping Yue, Catalin M Filipeanu, Eric Lazartigues
{"title":"UBR1 Promotes Sex-Dependent ACE2 Ubiquitination in Hypertension.","authors":"Mona Elgazzaz, Navya Lakkappa, Clara Berdasco, Uma Priya Mohan, Anna Nuzzo, Luke Restivo, Alexa Martinez, Amy Scarborough, Jessie J Guidry, Srinivas Sriramula, Jiaxi Xu, Hisham Daoud, Michelle A Mendiola Plá, Dawn E Bowles, Andreas M Beyer, Franck Mauvais-Jarvis, Xinping Yue, Catalin M Filipeanu, Eric Lazartigues","doi":"10.1161/HYPERTENSIONAHA.124.23196","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23196","url":null,"abstract":"<p><strong>Background: </strong>Ang-II (angiotensin II) impairs the function of the antihypertensive enzyme ACE2 (angiotensin-converting enzyme 2) by promoting its internalization, ubiquitination, and degradation, thus contributing to hypertension. However, few ACE2 ubiquitination partners have been identified, and their role in hypertension remains unknown.</p><p><strong>Methods: </strong>Proteomics and bioinformatic analyses were used to identify ACE2 ubiquitination partners in the brain, heart, and kidney of hypertensive C57BL6/J mice of both sexes. The interaction between UBR1 (ubiquitin protein ligase E3 component N-recognin) and ACE2 was validated in cells. Central and peripheral UBR1 knockdown was then performed in male mice to investigate its role in the maintenance of hypertension.</p><p><strong>Results: </strong>Proteomics analysis of the hypothalamus identified UBR1 as a potential E3 (ubiquitin protein ligase) ligase promoting ACE2 ubiquitination. Enhanced UBR1 expression, associated with ACE2 reduction, was confirmed in various tissues from hypertensive male mice and human samples. Treatment of endothelial and smooth muscle cells with testosterone, but not 17β-estradiol, confirmed a sex-specific regulation of UBR1. In vivo silencing of UBR1 using chronic administration of small interference RNA resulted in the restoration of ACE2 levels in hypertensive male mice. A transient decrease in blood pressure after intracerebroventricular, but not systemic, infusion was also observed. Interestingly, UBR1 knockdown increased brain activation of Nedd4-2 (neural precursor cell expressed developmentally downregulated protein 4), an E3 ligase promoting ACE2 ubiquitination, and reduced expression of serum and glucocorticoid-regulated kinase 1, the kinase that inactivates Nedd4-2.</p><p><strong>Conclusions: </strong>These data demonstrate that UBR1 is a novel E3 ubiquitin ligase targeting ACE2 in hypertension. UBR1 and Nedd4-2 appear to work synergistically to ubiquitinate ACE2. Targeting these ubiquitin ligases may represent a novel strategy to restore ACE2 compensatory activity in hypertension.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"84-95"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-11-21DOI: 10.1161/HYPERTENSIONAHA.124.23188
Jacquie R Baker, Paul A Beach, Shaun I Ranada, Aishani Patel, Jennifer Gewandter, Can Ozan Tan, Roy Freeman, Satish R Raj
{"title":"Cerebral Blood Flow Dynamics in Neurogenic Orthostatic Hypotension: A Systematic Review and Meta-Analysis.","authors":"Jacquie R Baker, Paul A Beach, Shaun I Ranada, Aishani Patel, Jennifer Gewandter, Can Ozan Tan, Roy Freeman, Satish R Raj","doi":"10.1161/HYPERTENSIONAHA.124.23188","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23188","url":null,"abstract":"<p><strong>Background: </strong>Neurogenic orthostatic hypotension (nOH) causes pathological falls in standing blood pressure that may or may not be symptomatic. nOH also raises the risk of poor neurological outcomes irrespective of symptom presence, possibly reflecting subclinical cerebral hypoperfusion. Dynamic changes in cerebral blood flow velocity (CBFv) help infer how blood pressure fluctuations influence CBFv and cerebral autoregulation. Whether CBFv is impacted in nOH relative to related conditions without nOH and healthy controls (HC) remains unresolved. Whether nOH symptoms reflect greater CBFv falls is also unclear. This review aimed to compare CBFv between nOH and HC, nOH and disease-matched controls (eg, Parkinson disease±nOH), and between symptomatic and asymptomatic nOH.</p><p><strong>Methods: </strong>Embase and MEDLINE were searched up to April 2024. Means, SDs, and sample sizes for supine and upright CBFv were extracted to generate standardized effect sizes (Hedge g). Random-effects modeling compared postintervention between-group effect sizes.</p><p><strong>Results: </strong>Seventeen studies were included for review. Thirteen studies were suitable for meta-analysis comparing nOH to HC, 2 comparing disease-matched controls to nOH and to HC, and 3 for symptomatic comparisons. Compared with HC, nOH had larger drops in CBFv (Hedge g, -0.64 [95% CI, -0.85 to -0.44]; <i>P</i><0.001). CBFv falls between nOH and disease-matched controls were similar (<i>P</i>=0.17). Symptomatic nOH had larger CBFv drops (Hedge g, 0.84 [95% CI, 0.212-1.461]; <i>P</i>=0.009) than asymptomatic nOH.</p><p><strong>Conclusions: </strong>nOH causes significant orthostatic reductions in CBFv compared with HC, and symptomatic patients experience greater falls in CBFv than asymptomatic patients. Recognizing the clinical implications of CBFv in nOH is crucial for mitigating adverse outcomes.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"106-117"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HypertensionPub Date : 2025-01-01Epub Date: 2024-07-16DOI: 10.1161/HYPERTENSIONAHA.123.22347
Patrick Dunn, Asif Ali, Akash P Patel, Srikanta Banerjee
{"title":"Brief Review and Primer of Key Terminology for Artificial Intelligence and Machine Learning in Hypertension.","authors":"Patrick Dunn, Asif Ali, Akash P Patel, Srikanta Banerjee","doi":"10.1161/HYPERTENSIONAHA.123.22347","DOIUrl":"10.1161/HYPERTENSIONAHA.123.22347","url":null,"abstract":"<p><p>Recent breakthroughs in artificial intelligence (AI) have caught the attention of many fields, including health care. The vision for AI is that a computer model can process information and provide output that is indistinguishable from that of a human and, in specific repetitive tasks, outperform a human's capability. The 2 critical underlying technologies in AI are used for supervised and unsupervised machine learning. Machine learning uses neural networks and deep learning modeled after the human brain from structured or unstructured data sets to learn, make decisions, and continuously improve the model. Natural language processing, used for supervised learning, is understanding, interpreting, and generating information using human language in chatbots and generative and conversational AI. These breakthroughs result from increased computing power and access to large data sets, setting the stage for releasing large language models, such as ChatGPT and others, and new imaging models using computer vision. Hypertension management involves using blood pressure and other biometric data from connected devices and generative AI to communicate with patients and health care professionals. AI can potentially improve hypertension diagnosis and treatment through remote patient monitoring and digital therapeutics.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"26-35"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}